跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 54 条关于
“VNPP433-3β”
全部
54
临床试验
11
药物
23
机构
0
资讯
20
上个月
Isoprene Pharmaceuticals Secures $1.02M NCI Grant to Advance Dual-Targeting Molecular Glue Degrader for Castration-Resistant Prostate Cancer
3个月前
Integrated Machine Learning and Molecular Dynamics Framework Identifies Novel GSK-3β Inhibitor Candidates for Alzheimer's Disease
去年
Actuate Therapeutics Raises $17.25 Million to Advance GSK-3β Inhibitor for Difficult-to-Treat Cancers
去年
Elraglusib Shows Promise for Advanced Salivary Gland Carcinoma in Upcoming AACR Presentation
11个月前
Gold Nanoparticle Nasal Spray Delivers Targeted Lithium Therapy to Brain for Neuropsychiatric Disorders
2年前
Elraglusib Receives FDA Orphan Drug Designation for Soft Tissue Sarcoma
去年
Actuate Therapeutics and Lantern Pharma Collaborate on AI-Driven Elraglusib Development
去年
Elraglusib Receives FDA Rare Pediatric Disease Designation for Ewing Sarcoma
3年前
Elraglusib Receives FDA Orphan Drug Designation for Pancreatic Cancer Treatment
去年
Elraglusib Receives EMA Orphan Drug Designation for Pancreatic Cancer Treatment
第 1 页,共 2 页
上一页
下一页